Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Jeff Gilbreth

Advertisement

Articles by Jeff Gilbreth

Part 3: How to Enforce Post-Employment Restrictions

ByFred Kelly,Jeff Gilbreth
April 22nd 2009

Courts are often hesitant to enforce such restrictions, so employers should take certain steps prior to and in the process of filing such a lawsuit.

Advertisement

Latest Updated Articles

  • Part 3: How to Enforce Post-Employment Restrictions
    Part 3: How to Enforce Post-Employment Restrictions

    April 22nd 2009



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia

2

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

3

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

4

Eli Lilly to Acquire AtaiBeckley for $2.8 Billion

5

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us